Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes
Victor Kamoen, et al
In 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide 2.4 mg cut the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20 percent over a mean follow-up of 39.8 months [9]
Tracking your progress not only helps your healthcare provider fine-tune your treatment but also gives you those encouraging reminders of how far you've come
Phang JM, Liu W, Hancock CN, Fischer JW
Journal reference: Johnson B, Milstead M, Thomas O, et al
US$ 23.93
US$ 20.19
US$ 29.90
US$ 23.75
